Trial Profile
A Pilot Feasibility Study of Durvalumab (MEDI4736) and Tremelimumab Following Radioembolization in Patients With Metastatic Microsatellite Stable (MSS) Colorectal Cancer to the Liver
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Colorectal cancer; Liver metastases
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 23 Dec 2019 Status changed from active, no longer recruiting to completed.
- 19 Dec 2018 Planned End Date changed from 1 Sep 2019 to 1 Dec 2019.
- 19 Dec 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Dec 2019.